StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Other (Income) Expense Breakdown by Quarter

Other (Income) Expense Breakdown — (Income) Loss on Equity Securities, Net ($M) ($M)

QuarterlyAnnual

Merck Other (Income) Expense Breakdown: -$242M in Q2 2026, up 142.0% from a year earlier.

Latest, Q2 2026
-242
Period ended Jun 30, 2026
Change on a year earlier
+142.0%
-100 in Q2 2025
History
26 quarters
Since Q1 2018
Sources
18
Documents cited below

Where the Q2 2026 figure comes from

“|| Income from investments in equity securities, net (1) | (242 | ) | (100 | ) | (411 | ) | (189 | )”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 8-K Table 4.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOther (Income) Expense Breakdown — (Income) Loss on Equity Securities, Net ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026-242+142.0%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 2025196+25.6%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 2025-373-1,303.2%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 2025-100+78.6%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 2025-90-37.1%Form 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2024Dec 31, 2024156-257.6%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 202431-6.1%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 2024-56-132.0%Form 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2024Mar 31, 2024-143–Form 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2023Dec 31, 2023-99-267.8%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 202333-91.1%Form 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2023Jun 30, 2023175-38.4%Form 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q4 2022Dec 31, 202259–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2022Sep 30, 2022371-154.3%Form 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗
Q2 2022Jun 30, 2022284–Form 8-K (tm2322190d1_ex99-1.htm, filed 2023-08-01) ↗
Q3 2021Sep 30, 2021-683+89.7%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗

Cite this data

StockData. (2026). Merck Other (Income) Expense Breakdown ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/other-inc-exp-eq-sec

See every metric in the Merck KPI table. Data updated Oct 26, 2026.